Within-class differences of the sulfonylureas should be accounted for. Reply to Schrijnders D, Kleefstra N and Landman GWD [letter]

Diabetologia. 2015 Jun;58(6):1376-7. doi: 10.1007/s00125-015-3574-z. Epub 2015 Mar 26.

Authors

Jonathan C Levy¹, Axel Riefflin, Rury R Holman

Affiliation

¹ Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ, UK, jonathan.levy@ocdem.ox.ac.uk.

PMID: 25810041
DOI: 10.1007/s00125-015-3574-z

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Blood Glucose / metabolism*
Diabetes Mellitus, Type 2 / drug therapy*
Female
Glyburide / therapeutic use*
Humans
Hypoglycemic Agents / therapeutic use*
Insulin / metabolism*
Insulin Secretion
Male

Substances

Blood Glucose
Hypoglycemic Agents
Insulin
Glyburide